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widespread high grade prostatic
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increase prostate cancer risk: results from
a multicenter biopsy study
Antonio Cicione1*, Cosimo De Nunzio2, Andrea Tubaro2, Francesco Cantiello1, Stefano Manno1, Carlos Oliveira3,
Estevao Lima3 and Rocco Damiano1Abstract
Background: To test in multicenter setting if patients affected of metabolic syndrome (MetS) and initial widespread
high grade prostatic intraepithelial neoplasia (wHGPIN) diagnosis are at higher risk of prostate cancer (PCa) on
repeat biopsy.
Methods: Patients clinical charts from three European Academic Hospital were reviewed in order to identify
patients with initial diagnosis of HGPIN undergone to repeat biopsy. Inclusion and exclusion criteria were adopted
to minimize patient heterogeneity. MetS was defined according to Word Heart Organization criteria while initial
wHGPIN when ≥4 cores biopsy were involved. A multivariate logistic model was computed to assess the
association between PCa and clinical-pathological variables.
Results: Overall 283 patients were scheduled. Median age was 67 years (IQR 62–72). MetS was diagnosed in
116/283 (41 %) patients and PCa was detected in 84/283 (29.7 %) patients.
In particular, PCa was more frequently diagnosed in patients affected of wHGPIN and MetS (45/86, 52.3 %)
than in patients with wHGPIN and normal metabolic profile (28/95, 29.5 %), p = 0.002. The multivariate logistic
model confirmed that wHGPIN and MetS are independent risk factors for following PCa diagnosis, respectively
OR 2.4 (95 % CI 1.01–5.71, p = 0.04), OR 2.79 (95 % CI 1.49–5.22, p = 0.01) while total PSA and DRE findings are not
able to predict PCa at repeat biopsy, OR 1.05 (95 % CI 0.98–1.03 p = 0.69) and OR 1.01 (95 % CI 0.55–1.84, p = 0.96)
respectively.
Conclusions: wHGPIN is positively associated to PCa; assessing metabolic profile and repeat prostate biopsy is
advisable in patients with initial diagnosis of wHGPIN.
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Table 1 Study criteria for Metabolic Syndrome (MetS) diagnosis
Diagnosis of MetS requires:
Insulin resistance, identified by 1 of the following:
Type 2 diabetes, Impaired fasting glucose, Impaired glucose tolerance,
or for those with normal fasting glucose levels (<110 mg/dL), glucose
uptake below the lowest quartile for background population under
investigation under hyperinsulinemic, euglycemic conditions
Plus any 2 of the following:
Antihypertensive medication and/or high blood pressure (≥140 mm
Hg systolic or ≥90 mm Hg diastolic)
Plasma triglycerides ≥150 mg/dL (≥1.7 mmol/L)
HDL cholesterol <35 mg/dL (<0.9 mmol/L) in men or <39 mg/dL
(1.0 mmol/L) in women
BMI >30 kg/m2 and/or waist:hip ratio >0.9 in men, >0.85 in women
Urinary albumin excretion rate ≥20 μg/min or albumin: creatinine
ratio ≥30 mg/g
Adapted from Grundy SM et al. [7]
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In 1986 McNeal and Bostwick introduced the patho-
logical diagnosis of high grade prostatic intraepithelial
cancer (HGPIN) as a preneoplastic lesion for prostate
cancer (PCa). From a histological point of view, it can
briefly be described as an atypical epithelial cell prolifer-
ation within preexistence acini or ducts with cytological
and molecular findings similar to cancer [1].
The clinical meaning of HGPIN is due to an upper risk
of subsequent prostate cancer detection. Although this risk
decreased to a median of 24 % since the introduction of 12
core template prostate biopsy, it is still higher than the risk
to detect PCa following a initial benign diagnosis [2]. Fur-
thermore the current EAU guideline have suggested early
repeat biopsy in case of extensive HGPIN diagnosis [3].
This advise is mainly due to the absence of clinical parame-
ters such as prostate specific antigen (PSA), digital rectal
examination (DRE) or imaging technique able to identify
which patients will have PCa on follow biopsy.
Therefore, new strategies are required to identify pa-
tients affected of HGPIN at higher risk of PCa in order
to reduce unnecessary prostate biopsies and to elucidate
prostate cancer carcinogenesis at same time. Some
evidences summarized by De Marzo et al. indicate the
chronic prostate inflammation as a potential cause of
prostatic cells overgrowth and oncogenesis [4, 5]. In this
context, metabolic syndrome (MetS) recognized as an
systemic inflammatory condition may act.
Our group has recently reported that patients with
HGPIN and MetS are at higher risk of prostate cancer
on subsequent biopsy [6]. However this initial finding re-
quires validation by more observations collected on dif-
ferent sets of patients [5].
Thus, the current study is designed to corroborate our
previous experience namely whether the diagnosis of
metabolic syndrome increases the risk of prostate cancer
in patients reporting an initial diagnosis of HGPIN.
Methods
Clinical charts from three tertiary academic centres were
reviewed to identify patients undergone to a repeat pros-
tate biopsy for initial diagnosis of HGPIN between De-
cember 2004 and March 2013.
Before initiation, This study was approved by the eth-
ics committee of Magna Graecia University, La Sapienza
University-Sant’Andrea Hospital and Braga Hospital that
provided the necessary institutional data-sharing agree-
ments. Furthermore, patients had signed a written con-
sent to prostate biopsies and clinical data access for
research purpose.
In order to minimize heterogeneity between centers
patients, inclusion and exclusion criteria were adopted
and all the data were included in a single common data-
sheet expressly created for the purpose.The main inclusion criteria was a repeat biopsy for ini-
tial diagnosis of HGPIN carried out by 6 months of ini-
tial biopsy instead of PSA level and DRE findings.
Furthermore a 12 core prostate biopsy scheme under
local anesthesia had to be adopted for both biopsies.
Patients receiving 5-Alpha reductase inhibitors, repeat
saturation biopsy or prostate transition zone sampling,
previous prostate surgery and concomitant diagnosis of
atypical small acinar proliferation (ASAP) were excluded
from the study.
Furthermore, World Health Organization (WHO) clin-
ical criteria (Table 1) [7] were adopted for diagnosis of
metabolic syndrome while widespread HGPIN was de-
fined when it was diagnosed in four or more than four
biopsy cores on initial prostate biopsy [8].
Clinical (age, prostate volume, BMI, DRE findings,
MetS and widespread diagnosis) and serum variables
(total and ratio PSA, HDL cholesterol level, plasma tri-
glycerides and fasting glucose) were analyzed in order to
identify significative difference between patients with
prostate cancer and benign diagnosis on repeat biopsy.Statistical analysis
Data showed a not normal distribution at Shapiro-Wilk
test. Whereby, data are presented in median value and
interquartile range (IQR: 25th–75th percentile) while
Mann Whitney and Chi-square test were respectively
utilized to test significative level of continuous and cat-
egorical variables.
Then to analyze the association between prostate can-
cer diagnosis at repeat biopsy and analyzed variables a
multivariate logistic regression model was used. All re-
ported p value are two-sided an significance was set at
0.05. Analysis was done by SPSS® 18.0 for Windows
(SPSS Inc., IBM Corp., Somers, NY, USA).
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Clinical records of two hundred and eighty three pa-
tients affected of HGPIN and undergone to a repeat
prostate biopsy were evaluated (Fig. 1).
Diagnosis of prostate cancer was reported in 84 pa-
tients (29.6 % of whole cohort) with a Gleason Score re-
spectively Six in 54 (64.6 %), Seven in 20 (24.7 %) and
Eight in 10 (12.7 %) patients. In the remaining patients,
a diagnosis of HGPIN in 166 patients (58.8 %) and pros-
tatitis in 33 (11.6 %) was reported.
Table 2 shows study population features related to
prostate cancer diagnosis or not on repeat biopsy. No
significative differences were found between patients
with or without prostate cancer in term of age, prostate
volume, BMI and DRE findings. Likewise, no significa-
tive differences were detected about total and ratio PSA,
HDL cholesterol, plasma triglycerides, fasting glucose
and hypertensive medication assumption between pa-
tients with cancer and benign diagnosis.
However, prostate cancer was more frequent in patients
with a previous diagnosis of wHGPIN than isolated
HGPIN: 73/181 (40.3 %) Vs 11/102 (10.2 %), p = 0.001.
Similarly, patients affected of MetS had PCa more recurrent
than patients with a normal metabolic status, respectively
54/116 (46.6 %) and 30/167 (18 %), p = 0.005. A similar
finding was achieved by analyzing also patients with initial
isolated HGPIN (≤=3 positive core) (data reported in
Table 1S of Additional file 1). Merely analyzing patients
with wHGPIN (Table 3), prostate cancer was more
frequently diagnosed in patients with MetS than patients
with normal metabolic profile, respectively 45/86 (52.3 %)
Vs 28/95 (29.5 %), p = 0.002. In particular, the diagnosed
Gleason Score was Six in 31/45 (68.8 %) and 19/28
(67.8 %), Seven in 10/45 (22.2 %) and 6/28 (21.4 %),
Eight in 4/45 (9 %) and 3/28 (10.8 %) patients affected
of wHGPIN and MetS or normal metabolic profile,
respectively.Fig. 1 Patients study flow chartFinally, the regression model confirmed that MetS diag-
nosis and wHGPIN are predictive variables for subsequent
PCa diagnosis (respectively OR 2.79, 95 % IC 1.49–5.22,
p = 0.01 and OR 2.4, 95 % IC 1.01–5.71, p = 0.04) while
PSA, PSA free, DRE findings, fasting glucose, blood
hypertension status, BMI, plasma triglycerides are not
able for that purpose (Table 4).
Discussion
HGPIN is still considered as a preneoplastic lesion. Epi-
demiological, molecular and morphological evidences sum-
marized by Montironi et al. underline reasons of HGPIN
may be prostate cancer precursor [9]. Albeit the risk of sub-
sequent prostate cancer in patient with initial diagnosis of
HGPIN has been reduced to 24 % since the introduction of
10 or 12-core prostate biopsy, it is higher than 18.7 % after
a benign diagnosis [2]. For this reason, EAU guidelines sug-
gest to perform a new early biopsy in case of extensive
HGPIN diagnosis [3] however it doesn’t suggest when.
This study confirms our previous result in a larger sam-
ple: patients affected of widespread HGPIN and Metabolic
Syndrome are at higher risk of prostate cancer [6]. A
chronic inflammatory environment due to MetS may ex-
plain this result. De Marzo et al. [4] proposed that chronic
prostatic inflammation may led to prostate cancer thought
progressive lesions where HGPIN may be the middle step.
Obesity, diabetes or insulin resistance and dyslipidemia
are conditions linked to inflammatory status by pro-
inflammatory cytokines secretion [10, 11]. For instance,
leptin and interleukin-6 showed in vitro to have a support-
ing activity in prostate cancer cell lines inducing prolifera-
tion, inhibiting apoptosis [12, 13] and increasing migration
[14]. Those bioactive substances are secreted by adipose
tissue with a well recognized pro-inflammatory activity.
Furthermore, they have also been found in high concentra-
tion in patient affected of HGPIN without prostate enlarge-
ment (prostate gland less than 40 ml) [15] supporting the
Table 4 Multivariate Regression Model analyzing predictive
variables of prostate cancer on repeat biopsy
Odds ratio 95 % CI p.
Total PSA 1.05 0.98 1.03 0.69
PSA Ratio 0.99 0.95 1.03 0.70
DRE 1.01 0.55 1.84 0.96
Table 2 Patients features related to diagnosis on repeat biopsy
Median - IQR Cancer No Cancer p-value a
84 (29.6 %) 199 (70.4 %)
Age 69.50 (64.0–75.5) 68.00 (62.0–73.0) 0.106
Prostate volume (cc) 48.50 (36.9–59.5) 50.00 (39.0–68.0) 0.337
DRE findings 0.780b
Normal 39/135 (28.9 %) 96/135 (71.1 %)
Suspect 45/148 (30.4 %) 103/148 (69.6 %)
Total PSA (ng/ml) 7.57 (4.8–8.1) 7.31 (6.06–8.4) 0.793
PSA Ratio (%) 14.00 (11.0–16.5) 14.00 (9.2–19) 0.852
Fasting glucose (mg/dL) 92.1 (64–147) 88.4 (72–151) 0.641
Antihypertensive medication or high blood pressure [No -%] 52 (61.9) 118 (59.2) 0.523b
BMI (Kg/m2) 27.78 (25.4–30.4) 27.38 (25.1–30.7) 0.244
HDL cholesterol (mg/dL) 45.00 (38.5–58.5) 47.00 (40–55) 0.915
Plasma Triglycerides (mg/dL) 125.50 (85–165.5) 133.00 (101–172) 0.131
HGPIN core on initial biopsy [No -%] 0.001b
< 4 11/102 (10.2 %) 91/102 (89.2 %)
≥ 4 73/181 (40.3 %) 108/181 (59.7 %)
MetS diagnosis [No -%] 0.005b
No 30/167 (18 %) 137/167 (82 %)
Yes 54/116 (46.6 %) 62/116 (53.4 %)
Mann Whitneya or Chi-square testb
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reason for carcinogenesis. In particular, the consequential
inflammatory microenvironment, produces reactive oxygen
and nitrogen radicals. These radicals may produce perman-
ent genomic alterations in cellular DNA including neoplas-
tic changes [5]. Indeed, HGPIN shares a number of
somatic genetic and epigenetic alterations with PCa. For
instance, about 20 % of HGPIN lesion harbour TMPRSS2-
ERG fusion gene, which is a common molecular abnormal-
ity detectable in about 50 % of prostate cancers [16] as well
as aneuploidy which is more frequent in HGPIN than be-
nign prostate tissue, although somewhat less than seen in
some invasive carcinomas [9].
In contrast to our previous study, each WHO meta-
bolic syndrome criteria has been also analyzed. It is in-
teresting to be noted that neither BMI, fasting glucose,
HDL and triglycerides level are independent PCa risk
factors on multivariate analysis whereas having MetSTable 3 Repeat biopsy diagnosis in patient with initial
widespread high grade prostatic intraepithelial neoplasia
diagnosis according to their metabolic profile




Metabolic syndrome 45/86 (52.3 %) 41/86 (47.7 %)
Normal metabolic profile 28/95 (29.5 %) 67/95 (70.5 %)
Chi-square test: p = 0.002diagnosis increases about two times that risk than pa-
tient with normal metabolic profile. To date, MetS is a
cluster of disorders and the true mechanism developing
cancer has to be known yet. Likely, it may be more com-
plex and be wary of the easy total sum from each meta-
bolic abnormalities consequences [10].
The main study limitation is its retrospective nature. Of
course, long prospective comparative study is thought as
the best method to evaluate a disease risk factor. Further-
more, including a hormonal profile assessment in suchFasting glucose 1.02 0.98 1.01 0.67
Antihypertensive medication
or high blood pressure
1.03 0.92 1.03 0.65
BMI 0.96 0.86 1.05 0.98
HDL cholesterol 0.84 0.72 1.06 0.80
Plasma Triglycerides 0.99 0.93 1.05 0.63
MetS Diagnosis 2.79 1.49 5.22 0.01
Widespread HGPIN 2.40 1.01 5.71 0.04
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understanding of likely cancer development way. How-
ever, this was an analysis of prospectively collected data
and the same biopsy sampling and method were used in
all the centers. Then, initial finding requires validation by
more observations, collected on different sets of patients
from different centers and retrospective study may be a quick
way for this [5]. In this context, the large sample has enabled
to corroborate previous results. First, Metabolic syndrome
may be considered a high risk factor for subsequent diagno-
sis of prostate cancer in patients with an initial diagnosis of
HGPIN. Then, widespread HGPIN is linked to higher risk of
prostate cancer at repeat biopsy. Lee et al. [17] reported an
increased risk of prostate cancer in patients affected of dif-
fuse and bilateral HGPIN. Merrimen JL [18] and De Nunzio
[19] showed as the risk of subsequent prostate cancer is
higher in case of a widespread HGPIN. However the small
sample was the main limit in each of those studies.
Finally, the lack of single uro-pathologist reviewing all
specimens is a further limit curbing our study findings
as well as absence of data on the number of biopsy core
positive in PCa.
As well as previous studies [2, 6, 17–19], neither total
and ratio PSA level and DRE findings are able to define
patients at higher PCa risk on subsequent biopsy.
Currently, there is not a single serum marker able to
find out patients with HGPIN at higher risk of subse-
quent PCa therefore new basic and clinical studies are
advisable to reduce the number on unnecessary prostate
biopsies. Our data suggest to asses metabolic profile in
patient with HGPIN diagnosis and repeat prostate bi-
opsy in case of metabolic syndrome is detected. Further-
more, our data prompt to assess if MetS and wHGPIN
may be thought as negative prognostic biopsy factors of
PCa since this cancer may be more aggressive in patients
affected of MetS [10].
However, further basic and very long prospective stud-
ies with careful interest on medications used for meta-
bolic syndrome are needed to clearly understand the
true association MetS- HGPIN- prostate cancer and to
investigate the possible protective or therapeutic role of
such medications.
Conclusions
Patients with an initial diagnosis of widespread HGPIN
and metabolic syndrome look to be at elevated risk of
subsequent prostate cancer diagnosis.
This study suggest that metabolic syndrome acts as
likely prostate cancer promoting factor at time of pre-
neoplastic lesion too. Furthermore, widespread HGPIN
as higher risk factor for subsequent prostate cancer diag-
nosis has also been confirmed in this large cohort study.
Then, repeating biopsy within six months from the pre-
vious one may be a advisable way to manage patientsaffected of wHGPIN as well as assessing metabolic profile
may be a further valid tool to identify patients at higher
PCa risk in order to reduce the number of unnecessary
prostate biopsies.
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